Key Takeaways
- Shares of vaccine makers dropped after Pfizer CFO David Denton mentioned the outlook for vaccine charges this yr obtained a “haircut.”
- Denton informed a convention that Pfizer anticipates a 24% U.S. vaccination charge this yr.
- Denton had mentioned beforehand the corporate would take steps to chop prices if COVID-19 vaccine income missed expectations.
Moderna (MRNA) was the worst-performing inventory within the S&P 500 as shares dropped 9% after Pfizer CFO David Denton mentioned the outlook for vaccine charges this yr obtained a big “haircut.” Pfizer (PFE) shares additionally dropped, declining 1%.
Denton informed a J.P. Morgan healthcare convention that Pfizer expects a 24% vaccination charge within the U.S. this yr, which equates to about 82 million injections. Moderna has estimated a spread of fifty million to 100 million.
Final week, Moderna and Pfizer, together with Pfizer’s companion BioNTech (BNTX), obtained Meals and Drug Administration (FDA) emergency use authorization for a brand new vaccine that targets presently circulating variants of the virus.
Denton added that the COVID-19 vaccine charge prediction is about half of that of the flu, so “we haircut that fairly considerably for the yr.” He famous that the corporate will “see how that performs out as we take a look at the tendencies within the coming weeks within the U.S. and globally from that perspective.”
Demand for COVID-19 photographs has plunged because the pandemic waned and after hundreds of thousands had already been vaccinated. Final month, Denton famous that if COVID-19 vaccine gross sales had been lower than Pfizer assumed, “we’re ready to launch an enterprise-wide value enchancment program aligned with the longer-term income projections for our enterprise.”
American Depositary Receipts (ADRs) of BioNTech additionally fell 3.8% following the information.
YCharts